BioNTech (NASDAQ:BNTX) PT Raised to $98.00

BioNTech (NASDAQ:BNTX) had its price objective upped by analysts at TD Cowen from $95.00 to $98.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “hold” rating on the stock. TD Cowen’s price objective points to a potential upside of 8.73% from the stock’s current price.

Several other equities analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $107.00 price target on shares of BioNTech in a report on Wednesday, April 17th. BMO Capital Markets lowered their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday. UBS Group dropped their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, BioNTech presently has a consensus rating of “Hold” and a consensus target price of $118.82.

BioNTech Price Performance

Shares of BNTX opened at $90.13 on Tuesday. The stock has a market cap of $21.43 billion, a P/E ratio of 21.88 and a beta of 0.25. BioNTech has a 1 year low of $85.21 and a 1 year high of $125.83. The stock’s 50-day moving average price is $90.47 and its two-hundred day moving average price is $95.95. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. On average, equities analysts predict that BioNTech will post -1.74 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the company. Baillie Gifford & Co. lifted its position in shares of BioNTech by 1.0% in the fourth quarter. Baillie Gifford & Co. now owns 8,689,182 shares of the company’s stock worth $917,056,000 after purchasing an additional 86,343 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock valued at $502,735,000 after acquiring an additional 131,490 shares in the last quarter. Harding Loevner LP acquired a new stake in shares of BioNTech in the fourth quarter valued at about $410,984,000. Flossbach Von Storch AG raised its holdings in BioNTech by 1.0% during the fourth quarter. Flossbach Von Storch AG now owns 3,548,660 shares of the company’s stock worth $374,526,000 after acquiring an additional 35,445 shares in the last quarter. Finally, Capital World Investors boosted its position in BioNTech by 1.5% during the fourth quarter. Capital World Investors now owns 938,747 shares of the company’s stock valued at $99,075,000 after purchasing an additional 14,027 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.